| Protocols | ||
|---|---|---|
| 6 protocol(s) meet the specified criteria | ||
| Drug: CYTOSAR-U | ||
| Protocol No. | Title | Status |
| A041501-CIRB | A Phase III Trial To Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39) with Newly Diagnosed Precursor B-Cell ALL | Open |
| AALL1131 | A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | Open |
| AAML1031 | A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD | Open |
| E1910 | A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults. | Open |
| TPI-ALV-101 | A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) | Open |
| TPI-ALV-201 | A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) | Open |